Total Payments
$97,416
2024 Payments
$3,335
Companies
15
Transactions
73
Medicare Patients
1,120
Medicare Billing
$97,742
Payment Breakdown by Category
Consulting$67,137 (68.9%)
Other$23,605 (24.2%)
Research$2,541 (2.6%)
Travel$2,275 (2.3%)
Food & Beverage$1,665 (1.7%)
Education$192.96 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $67,137 | 27 | 68.9% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $9,960 | 3 | 10.2% |
| Compensation for serving as faculty or as a speaker for a medical education program | $8,645 | 2 | 8.9% |
| Honoraria | $5,000 | 1 | 5.1% |
| Unspecified | $2,541 | 16 | 2.6% |
| Travel and Lodging | $2,275 | 4 | 2.3% |
| Food and Beverage | $1,665 | 17 | 1.7% |
| Education | $192.96 | 3 | 0.2% |
Payments by Type
General
$94,875
57 transactions
Research
$2,541
16 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GlaxoSmithKline, LLC. | $34,560 | 20 | $0 (2023) |
| Ipsen Innovation | $17,775 | 5 | $0 (2024) |
| INTERCEPT PHARMACEUTICALS, INC. | $14,384 | 12 | $0 (2023) |
| Takeda Pharmaceuticals U.S.A., Inc. | $7,700 | 2 | $0 (2020) |
| Ipsen Biopharmaceuticals, Inc | $6,225 | 2 | $0 (2023) |
| Kowa Research Institute, Inc. | $4,184 | 5 | $0 (2024) |
| Gilead Sciences, Inc. | $3,691 | 15 | $0 (2024) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $3,618 | 3 | $0 (2022) |
| ALBIREO PHARMA, INC. | $2,612 | 1 | $0 (2022) |
| Ipsen Bioscience Inc | $1,383 | 1 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,335 | 5 | Ipsen Innovation ($1,660) |
| 2023 | $35,728 | 16 | GlaxoSmithKline, LLC. ($14,219) |
| 2022 | $32,966 | 15 | GlaxoSmithKline, LLC. ($14,300) |
| 2021 | $5,393 | 5 | GlaxoSmithKline, LLC. ($2,600) |
| 2020 | $10,788 | 6 | Takeda Pharmaceuticals U.S.A., Inc. ($7,700) |
| 2019 | $1,630 | 11 | Gilead Sciences, Inc. ($1,558) |
| 2018 | $118.03 | 2 | Intercept Pharmaceuticals, Inc. ($93.84) |
| 2017 | $7,459 | 13 | Intercept Pharmaceuticals, Inc. ($6,454) |
All Payment Transactions
73 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/19/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $96.44 | General |
| 11/14/2024 | Gilead Sciences, Inc. | Livdelzi (Drug) | Food and Beverage | In-kind items and services | $106.06 | General |
| Category: INFLAM | ||||||
| 03/21/2024 | Kowa Research Institute, Inc. | — | Travel and Lodging | Cash or cash equivalent | $1,096.89 | General |
| 03/21/2024 | Kowa Research Institute, Inc. | — | Food and Beverage | Cash or cash equivalent | $375.38 | General |
| 01/15/2024 | Ipsen Innovation | — | Consulting Fee | Cash or cash equivalent | $1,660.00 | General |
| 12/11/2023 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $3,200.00 | General |
| 12/08/2023 | Ipsen Biopharmaceuticals, Inc | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,320.00 | General |
| 12/07/2023 | Kowa Research Institute, Inc. | — | Food and Beverage | Cash or cash equivalent | $211.43 | General |
| 11/27/2023 | Kowa Research Institute, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,000.00 | General |
| 08/10/2023 | Mallinckrodt Hospital Products Inc. | TERLIVAZ (Drug) | Food and Beverage | In-kind items and services | $17.71 | General |
| Category: CRITICAL CARE | ||||||
| 08/04/2023 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $3,200.00 | General |
| 08/04/2023 | GlaxoSmithKline, LLC. | — | Travel and Lodging | Cash or cash equivalent | $18.50 | General |
| 07/21/2023 | Ipsen Innovation | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,735.00 | General |
| 07/21/2023 | Ipsen Innovation | — | Consulting Fee | Cash or cash equivalent | $3,735.00 | General |
| 07/21/2023 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $2,600.00 | General |
| 06/28/2023 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $19.20 | General |
| 06/20/2023 | INTERCEPT PHARMACEUTICALS, INC. | OCALIVA (Drug) | Food and Beverage | In-kind items and services | $116.11 | General |
| Category: Hepatology / Gastroenterology | ||||||
| 03/17/2023 | INTERCEPT PHARMACEUTICALS, INC. | OCALIVA (Drug) | Consulting Fee | Cash or cash equivalent | $4,949.68 | General |
| Category: Hepatology / Gastroenterology | ||||||
| 03/13/2023 | Ipsen Biopharmaceuticals, Inc | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,905.00 | General |
| 02/24/2023 | Kowa Research Institute, Inc. | — | Consulting Fee | Cash or cash equivalent | $500.00 | General |
| 01/24/2023 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $5,200.00 | General |
| 11/22/2022 | ALBIREO PHARMA, INC. | Bylvay (Drug) | Consulting Fee | Cash or cash equivalent | $2,612.00 | General |
| Category: Gastroenterology | ||||||
| 10/19/2022 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $2,600.00 | General |
| 10/18/2022 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $7,800.00 | General |
| 07/27/2022 | Ipsen Innovation | — | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $2,835.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Subjects with Primary Sclerosing Cholangitis | Gilead Sciences, Inc. | $1,537 | 9 |
| A randomized, double blind, multi dose, placebo controlled study to evaluate the efficacy, safety and tolerability of GSK2330672 administration for the treatment of pruritus in patients with primary biliary cholangitis | GlaxoSmithKline, LLC. | $1,004 | 7 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 239 | 275 | $102,678 | $20,097 |
| 2022 | 10 | 293 | 338 | $122,422 | $24,588 |
| 2021 | 8 | 271 | 318 | $104,997 | $24,066 |
| 2020 | 11 | 317 | 390 | $138,117 | $28,991 |
Total Patients
1,120
Total Services
1,321
Medicare Billing
$97,742
Procedure Codes
39
All Medicare Procedures & Services
39 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 74 | 91 | $27,209 | $6,974 | 25.6% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 22 | 35 | $13,965 | $3,622 | 25.9% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 22 | 22 | $13,486 | $2,215 | 16.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 21 | 21 | $10,647 | $2,140 | 20.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 37 | 40 | $7,720 | $2,122 | 27.5% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 15 | 15 | $15,960 | $1,442 | 9.0% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 14 | 16 | $4,416 | $1,101 | 24.9% |
| 91200 | Measurement of liver stiffness | Office | 2023 | 13 | 13 | $3,445 | $285.23 | 8.3% |
| 91200 | Measurement of liver stiffness | Facility | 2023 | 21 | 22 | $5,830 | $195.14 | 3.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 94 | 107 | $31,993 | $7,816 | 24.4% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 22 | 44 | $17,556 | $3,873 | 22.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 26 | 26 | $13,182 | $2,863 | 21.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 43 | 49 | $9,457 | $2,672 | 28.3% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 21 | 23 | $14,099 | $2,296 | 16.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 15 | 16 | $6,864 | $1,895 | 27.6% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2022 | 12 | 12 | $12,768 | $1,162 | 9.1% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 11 | 12 | $3,312 | $737.16 | 22.3% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Facility | 2022 | 12 | 12 | $3,648 | $693.76 | 19.0% |
| 91200 | Measurement of liver stiffness | Office | 2022 | 15 | 15 | $3,975 | $390.90 | 9.8% |
| 91200 | Measurement of liver stiffness | Facility | 2022 | 22 | 22 | $5,568 | $189.51 | 3.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 88 | 107 | $31,993 | $8,478 | 26.5% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 21 | 38 | $15,162 | $3,420 | 22.6% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 22 | 23 | $9,867 | $2,847 | 28.8% |
| 43239 | Biopsy of the esophagus, stomach, and/or upper small bowel using an endoscope | Facility | 2021 | 29 | 30 | $18,390 | $2,776 | 15.1% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Facility | 2021 | 21 | 21 | $10,647 | $2,558 | 24.0% |
About Dr. Cynthia Levy, MD
Dr. Cynthia Levy, MD is a Gastroenterology healthcare provider based in Miami, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/10/2006. The National Provider Identifier (NPI) number assigned to this provider is 1215979901.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Cynthia Levy, MD has received a total of $97,416 in payments from pharmaceutical and medical device companies, with $3,335 received in 2024. These payments were reported across 73 transactions from 15 companies. The most common payment nature is "Consulting Fee" ($67,137).
As a Medicare-enrolled provider, Levy has provided services to 1,120 Medicare beneficiaries, totaling 1,321 services with total Medicare billing of $97,742. Data is available for 4 years (2020–2023), covering 39 distinct procedure/service records.
Ad
Practice Information
- Specialty Gastroenterology
- Other Specialties Hepatology
- Location Miami, FL
- Active Since 06/10/2006
- Last Updated 05/10/2017
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1215979901
Products in Payments
- OCALIVA (Drug) $7,858
- OCA (Drug) $6,454
- XIFAXAN (Drug) $3,618
- Bylvay (Drug) $2,612
- GIVLAARI (Drug) $192.96
- Livdelzi (Drug) $106.06
- Mavyret (Drug) $24.19
- TERLIVAZ (Drug) $17.71
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in Miami
Dr. Jerry Martel, M.d., M.p.h, M.D., M.P.H
Gastroenterology — Payments: $454,127
Gastroenterology $454,127
Andres Gelrud, M.d, M.D
Gastroenterology — Payments: $381,307
Gastroenterology $381,307
George Sanchez, Md, MD
Gastroenterology — Payments: $122,469
Gastroenterology $122,469
Jodie Barkin, M.d, M.D
Gastroenterology — Payments: $119,372
Gastroenterology $119,372
Sunil Amin, Md, MD
Gastroenterology — Payments: $102,696
Gastroenterology $102,696
James Leavitt, M.d, M.D
Gastroenterology — Payments: $36,716
Gastroenterology $36,716